| 000 | 01907 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250518070004.0 | ||
| 264 | 0 | _c20200914 | |
| 008 | 202009s 0 0 eng d | ||
| 022 | _a1935-5548 | ||
| 024 | 7 |
_a10.2337/dc19-1328 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPettus, Jeremy H | |
| 245 | 0 | 0 |
_aEfficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study. _h[electronic resource] |
| 260 |
_bDiabetes care _c01 2020 |
||
| 300 |
_a161-168 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAlkanesulfonates _xadministration & dosage |
| 650 | 0 | 4 |
_aBenzamides _xadministration & dosage |
| 650 | 0 | 4 |
_aBlood Glucose _xdrug effects |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aDrug Resistance _xdrug effects |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMetformin _xtherapeutic use |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aReceptors, Glucagon _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aD'Alessio, David | |
| 700 | 1 | _aFrias, Juan P | |
| 700 | 1 | _aVajda, Eric G | |
| 700 | 1 | _aPipkin, James D | |
| 700 | 1 | _aRosenstock, Julio | |
| 700 | 1 | _aWilliamson, Gretchen | |
| 700 | 1 | _aZangmeister, Miriam A | |
| 700 | 1 | _aZhi, Lin | |
| 700 | 1 | _aMarschke, Keith B | |
| 773 | 0 |
_tDiabetes care _gvol. 43 _gno. 1 _gp. 161-168 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2337/dc19-1328 _zAvailable from publisher's website |
| 999 |
_c30281331 _d30281331 |
||